» Articles » PMID: 39380060

The New Advance of Exosome-based Liquid Biopsy for Cancer Diagnosis

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2024 Oct 8
PMID 39380060
Authors
Affiliations
Soon will be listed here.
Abstract

Liquid biopsy is a minimally invasive method that uses biofluid samples instead of tissue samples for cancer diagnosis. Exosomes are small extracellular vesicles secreted by donor cells and act as mediators of intercellular communication in human health and disease. Due to their important roles, exosomes have been considered as promising biomarkers for liquid biopsy. However, traditional methods for exosome isolation and cargo detection methods are time-consuming and inefficient, limiting their practical application. In the past decades, many new strategies, such as microfluidic chips, nanowire arrays and electrochemical biosensors, have been proposed to achieve rapid, accurate and high-throughput detection and analysis of exosomes. In this review, we discussed about the new advance in exosome-based liquid biopsy technology, including isolation, enrichment, cargo detection and analysis approaches. The comparison of currently available methods is also included. Finally, we summarized the advantages and limitations of the present strategies and further gave a perspective to their future translational use.

Citing Articles

A Novel Microfluidic Platform for Personalized Anticancer Drug Screening Through Image Analysis.

Lipreri M, Totaro M, Boos J, Basile M, Baldini N, Avnet S Micromachines (Basel). 2025; 15(12.

PMID: 39770275 PMC: 11677617. DOI: 10.3390/mi15121521.


Isolation of Plasma Extracellular Vesicles for High-Depth Analysis of Proteomic Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients.

Arafa A, Ludwig M, Tuncer O, Kollitz L, Gustafson A, Boytim E Cancers (Basel). 2025; 16(24).

PMID: 39766159 PMC: 11674840. DOI: 10.3390/cancers16244261.


Diagnostic and Prognostic Significance of Exosomes and Their Components in Patients With Cancers.

Moni Z, Hasan Z, Alam M, Roy N, Islam F Cancer Med. 2025; 14(1):e70569.

PMID: 39757782 PMC: 11702466. DOI: 10.1002/cam4.70569.

References
1.
Yu W, Hurley J, Roberts D, Chakrabortty S, Enderle D, Noerholm M . Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021; 32(4):466-477. PMC: 8268076. DOI: 10.1016/j.annonc.2021.01.074. View

2.
Hinestrosa J, Sears R, Dhani H, Lewis J, Schroeder G, Balcer H . Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma. Commun Med (Lond). 2023; 3(1):146. PMC: 10587093. DOI: 10.1038/s43856-023-00351-4. View

3.
Su X, Liu X, Xie Y, Chen M, Zheng C, Zhong H . Integrated SERS-Vertical Flow Biosensor Enabling Multiplexed Quantitative Profiling of Serological Exosomal Proteins in Patients for Accurate Breast Cancer Subtyping. ACS Nano. 2023; 17(4):4077-4088. DOI: 10.1021/acsnano.3c00449. View

4.
Liu X, Guo Q, Gao G, Cao Z, Guan Z, Jia B . Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. J Nanobiotechnology. 2023; 21(1):45. PMC: 9906870. DOI: 10.1186/s12951-023-01801-w. View

5.
Chen H, Huang C, Wu Y, Sun N, Deng C . Exosome Metabolic Patterns on Aptamer-Coupled Polymorphic Carbon for Precise Detection of Early Gastric Cancer. ACS Nano. 2022; 16(8):12952-12963. DOI: 10.1021/acsnano.2c05355. View